Do analysts rate ABP or BRTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Biorestorative Therapies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate CDIO or ABP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is CDIO or ABP more profitable?

Abpro has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Abpro's return on equity of 0.00% beat Cardio Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Cardio Diagnostics -43,133.33% -82.28% -76.03% Abpro N/A N/A -344.76%

Do analysts recommend BCAB or ABP?

BioAtla currently has a consensus target price of $200.00, indicating a potential upside of 11,394.25%. Given BioAtla's stronger consensus rating and higher possible upside, equities research analysts plainly believe BioAtla is more favorable than Abpro. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is BCAB or ABP more profitable?

Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -289.67% Abpro N/A N/A -344.76%

Do analysts prefer ABP or LABT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, ABP or LABT?

Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abpro N/A N/A -$7.23M -$4.23 N/A Lakewood-Amedex Biotherapeutics N/A N/A -$3.85M -$4.75 N/A

Is ABP or LABT more profitable?

Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% Lakewood-Amedex Biotherapeutics N/A N/A N/A

Do analysts recommend ABP or EVGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ABP or EVGN more profitable?

Abpro has a net margin of 0.00% compared to Evogene's net margin of -694.18%. Abpro's return on equity of 0.00% beat Evogene's return on equity. Company Net Margins Return on Equity Return on Assets Abpro N/A N/A -344.76% Evogene -694.18% -156.53% -86.80%

Abpro (ABP) Competitors

$0.52 0.00 (0.00%)

As of 08/28/2026

Compare

ABP vs. BRTX, CDIO, BCAB, LABT, and EVGN

Should you buy Abpro stock or one of its competitors? Abpro's main competitors and comparable companies include Biorestorative Therapies (BRTX), Cardio Diagnostics (CDIO), BioAtla (BCAB), Lakewood-Amedex Biotherapeutics (LABT), and Evogene (EVGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Abpro compare to Biorestorative Therapies?

Abpro (NASDAQ:ABP) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Abpro has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Abpro's return on equity of 0.00% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Biorestorative Therapies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Biorestorative Therapies had 2 more articles in the media than Abpro. MarketBeat recorded 2 mentions for Biorestorative Therapies and 0 mentions for Abpro. Biorestorative Therapies' average media sentiment score of 1.44 beat Abpro's score of 0.00 indicating that Biorestorative Therapies is being referred to more favorably in the news media.

Company	Overall Sentiment
Abpro	Neutral
Biorestorative Therapies	Positive

23.3% of Abpro shares are held by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are held by institutional investors. 13.7% of Abpro shares are held by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Abpro has higher earnings, but lower revenue than Biorestorative Therapies. Biorestorative Therapies is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Biorestorative Therapies	$357.87K	14.17	-$14.24M	-$1.07	N/A

Summary

Abpro and Biorestorative Therapies tied by winning 6 of the 12 factors compared between the two stocks.

How does Abpro compare to Cardio Diagnostics?

Cardio Diagnostics (NASDAQ:CDIO) and Abpro (NASDAQ:ABP) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Cardio Diagnostics has higher revenue and earnings than Abpro. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10K	547.60	-$6.50M	-$2.92	N/A
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A

In the previous week, Cardio Diagnostics had 2 more articles in the media than Abpro. MarketBeat recorded 2 mentions for Cardio Diagnostics and 0 mentions for Abpro. Cardio Diagnostics' average media sentiment score of 1.25 beat Abpro's score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Cardio Diagnostics	Positive
Abpro	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 23.3% of Abpro shares are held by institutional investors. 9.0% of Cardio Diagnostics shares are held by company insiders. Comparatively, 13.7% of Abpro shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Abpro has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Abpro's return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%
Abpro	N/A	N/A	-344.76%

Summary

Cardio Diagnostics and Abpro tied by winning 6 of the 12 factors compared between the two stocks.

How does Abpro compare to BioAtla?

BioAtla (NASDAQ:BCAB) and Abpro (NASDAQ:ABP) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

In the previous week, BioAtla had 1 more articles in the media than Abpro. MarketBeat recorded 1 mentions for BioAtla and 0 mentions for Abpro. BioAtla's average media sentiment score of 1.89 beat Abpro's score of 0.00 indicating that BioAtla is being referred to more favorably in the media.

Company	Overall Sentiment
BioAtla	Very Positive
Abpro	Neutral

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-289.67%
Abpro	N/A	N/A	-344.76%

Abpro has lower revenue, but higher earnings than BioAtla. Abpro is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	1.45	-$59.61M	-$25.45	N/A
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A

BioAtla currently has a consensus target price of $200.00, indicating a potential upside of 11,394.25%. Given BioAtla's stronger consensus rating and higher possible upside, equities research analysts plainly believe BioAtla is more favorable than Abpro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

77.2% of BioAtla shares are held by institutional investors. Comparatively, 23.3% of Abpro shares are held by institutional investors. 9.3% of BioAtla shares are held by company insiders. Comparatively, 13.7% of Abpro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

BioAtla beats Abpro on 9 of the 12 factors compared between the two stocks.

How does Abpro compare to Lakewood-Amedex Biotherapeutics?

Abpro (NASDAQ:ABP) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Lakewood-Amedex Biotherapeutics	N/A	N/A	-$3.85M	-$4.75	N/A

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A

23.3% of Abpro shares are owned by institutional investors. 13.7% of Abpro shares are owned by insiders. Comparatively, 5.4% of Lakewood-Amedex Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Lakewood-Amedex Biotherapeutics had 3 more articles in the media than Abpro. MarketBeat recorded 3 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for Abpro. Lakewood-Amedex Biotherapeutics' average media sentiment score of 1.27 beat Abpro's score of 0.00 indicating that Lakewood-Amedex Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Abpro	Neutral
Lakewood-Amedex Biotherapeutics	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Abpro beats Lakewood-Amedex Biotherapeutics on 5 of the 9 factors compared between the two stocks.

How does Abpro compare to Evogene?

Abpro (NASDAQ:ABP) and Evogene (NASDAQ:EVGN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Evogene had 6 more articles in the media than Abpro. MarketBeat recorded 6 mentions for Evogene and 0 mentions for Abpro. Evogene's average media sentiment score of 0.14 beat Abpro's score of 0.00 indicating that Evogene is being referred to more favorably in the news media.

Company	Overall Sentiment
Abpro	Neutral
Evogene	Neutral

23.3% of Abpro shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 13.7% of Abpro shares are held by insiders. Comparatively, 7.4% of Evogene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Abpro has a net margin of 0.00% compared to Evogene's net margin of -694.18%. Abpro's return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Evogene	-694.18%	-156.53%	-86.80%

Abpro has higher earnings, but lower revenue than Evogene. Evogene is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abpro	N/A	N/A	-$7.23M	-$4.23	N/A
Evogene	$3.85M	1.24	-$8.48M	-$0.91	N/A

Summary

Abpro beats Evogene on 7 of the 12 factors compared between the two stocks.

Get Abpro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABP vs. The Competition

Export

Metric	Abpro	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.42M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-0.12	11.62	273.16	25.45
Price / Sales	N/A	1,293.26	604.87	76.92
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	-0.06	16.53	12.98	6.14
Net Income	-$7.23M	-$22.80M	$3.48B	$348.86M
7 Day Performance	N/A	-0.31%	0.13%	-0.80%
1 Month Performance	N/A	9.80%	7.08%	4.13%
1 Year Performance	-92.90%	55.66%	24.67%	15.17%

Abpro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABP Abpro	N/A	$0.52 flat	N/A	N/A	$1.42M	N/A	N/A	15
BRTX Biorestorative Therapies	1.3371 of 5 stars	$0.22 -2.5%	N/A	-89.2%	$5.67M	$360K	N/A	7	Short Interest Decrease Gap Up
CDIO Cardio Diagnostics	0.7239 of 5 stars	$1.93 +1.0%	N/A	-52.2%	$5.65M	$10K	N/A	1	News Coverage Positive News
BCAB BioAtla	1.9082 of 5 stars	$3.12 -4.3%	$200.00 +6,310.3%	-92.4%	$5.43M	$2M	N/A	60	Positive News Gap Down
LABT Lakewood-Amedex Biotherapeutics	0.8363 of 5 stars	$2.45 +7.0%	N/A	N/A	$5.43M	N/A	N/A	5	News Coverage Positive News Analyst Downgrade Short Interest Decrease Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABP) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abpro (ABP) Competitors

ABP vs. BRTX, CDIO, BCAB, LABT, and EVGN

How does Abpro compare to Biorestorative Therapies?

Summary

How does Abpro compare to Cardio Diagnostics?

Summary

How does Abpro compare to BioAtla?

Summary

How does Abpro compare to Lakewood-Amedex Biotherapeutics?

Summary

How does Abpro compare to Evogene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP vs. The Competition

Abpro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abpro (ABP) Competitors

ABP vs. BRTX, CDIO, BCAB, LABT, and EVGN

How does Abpro compare to Biorestorative Therapies?

Is ABP or BRTX more profitable?

Do analysts rate ABP or BRTX?

Does the media refer more to ABP or BRTX?

Do institutionals & insiders hold more shares of ABP or BRTX?

Which has better earnings & valuation, ABP or BRTX?

Summary

How does Abpro compare to Cardio Diagnostics?

Which has stronger earnings & valuation, CDIO or ABP?

Does the media favor CDIO or ABP?

Do analysts rate CDIO or ABP?

Do insiders & institutionals hold more shares of CDIO or ABP?

Is CDIO or ABP more profitable?

Summary

How does Abpro compare to BioAtla?

Does the media refer more to BCAB or ABP?

Is BCAB or ABP more profitable?

Which has preferable valuation and earnings, BCAB or ABP?

Do analysts recommend BCAB or ABP?

Do institutionals and insiders have more ownership in BCAB or ABP?

Summary

How does Abpro compare to Lakewood-Amedex Biotherapeutics?

Which has preferable earnings and valuation, ABP or LABT?

Is ABP or LABT more profitable?

Do institutionals & insiders have more ownership in ABP or LABT?

Does the media favor ABP or LABT?

Do analysts prefer ABP or LABT?

Summary

How does Abpro compare to Evogene?

Do analysts recommend ABP or EVGN?

Does the media prefer ABP or EVGN?

Do insiders & institutionals believe in ABP or EVGN?

Is ABP or EVGN more profitable?

Which has preferable valuation and earnings, ABP or EVGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABP vs. The Competition

Abpro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools